MEDNAX INC's ticker is MD and the CUSIP is 58502B106. A total of 213 filers reported holding MEDNAX INC in Q2 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BANK OF MONTREAL /CAN/ | 56,334 | $811,209 | 0.00% |
| Parallel Advisors, LLC | 504 | $7,162 | 0.00% |
| DEUTSCHE BANK AG\ | 37,345 | $530,672 | 0.00% |
| BARROW HANLEY MEWHINNEY & STRAUSS LLC | 719 | $10,217 | 0.00% |
| FMR LLC | 12,488 | $177,454 | 0.00% |
| FIFTH THIRD BANCORP | 308 | $4,377 | 0.00% |
| Bollard Group LLC | 183 | $3 | 0.00% |
| US BANCORP \DE\ | 2,275 | $32,328 | 0.00% |
| PNC FINANCIAL SERVICES GROUP, INC. | 12,548 | $178,307 | 0.00% |
| STIFEL FINANCIAL CORP | 15,097 | $214,528 | 0.00% |
| JANE STREET GROUP, LLC | 52,083 | $740,099 | 0.00% |
| Allworth Financial LP | 23 | $327 | 0.00% |
| Allianz Asset Management GmbH | 590,243 | $8,387 | 0.00% |
| Point72 Asset Management, L.P. | 51 | $725 | 0.00% |
| AMERICAN CENTURY COMPANIES INC | 28,907 | $410,768 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 206 | $2,927 | 0.00% |
| UBS Group AG | 82,669 | $1,174,727 | 0.00% |
| WASHINGTON TRUST Co | 98 | $1,393 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 55,706 | $792 | 0.00% |
| Glassman Wealth Services | 114 | $1,620 | 0.00% |
About MEDNAX INC
MEDNAX Inc. is a leading provider of physician services, including neonatal, anesthesia, maternal-fetal, and pediatric subspecialty care. The company operates in all 50 states and Puerto Rico, serving over 6 million patients annually.
MEDNAX has a strong reputation for providing high-quality care and has been recognized for its clinical excellence by numerous organizations. The company's commitment to patient care is reflected in its mission statement, which states that it is "dedicated to improving the quality of patient care through clinical excellence and innovation."
In recent years, MEDNAX has faced some challenges, including declining revenue and a decrease in patient volume. However, the company has taken steps to address these issues, including divesting non-core businesses and implementing cost-saving measures.
Despite these challenges, MEDNAX remains a strong player in the healthcare industry, with a diverse portfolio of services and a commitment to providing high-quality care. The company's leadership team, including CEO Mark S. Ordan and COO Stephen D. Farber, has a wealth of experience in the healthcare industry and is well-positioned to guide the company through any future challenges.
Overall, MEDNAX is a company with a strong reputation for clinical excellence and a commitment to providing high-quality care to patients. While the company has faced some challenges in recent years, it remains a leader in the healthcare industry and is well-positioned for future success.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists MEDNAX INC's shareholders in Q2 2023. To view MEDNAX INC's shareholder history, click here.